María Moreno-Sastre

María Moreno-Sastre

Auto-generated profile, based on publicly available information

María Moreno-Sastre

A NanoBioCel Group, Laboratory of Pharmaceutics , School of Pharmacy, University of the Basque Country (UPV/EHU) , Vitoria-Gasteiz , Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MMM. Moreno-Sastre
M. Moreno-Sastre
MPM. Pastor
M. Pastor
Claudio SalomonClaudio Salomon
Claudio Salomon
AEA. Esquisabel
A. Esquisabel
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz
As the WHO stated, lower respiratory infections are the third leading cause of death. In addition, it is remarkable that antimicrobial resistance represents a huge threat. Thus, new therapeutic weapons are required. Among the possible alternatives, antibiotic encapsulation in nanoparticles has gained much attention in terms of improved tolerability, activity and ability to combat the resistance mechanisms of bacteria. In this regard, this review article focuses on the latest nanocarrier approaches for inhalatory therapy of antibiotics. First, the technology related to lung disposition will be reviewed. Then, nanocarrier systems will be introduced and the challenges required to perform adequate pulmonary deposition analysed. In the following part, drug delivery systems (DDSs) on the market or in clinical trials are described and, finally, new approaches of nanoparticles that have reached pre-clinical stage are enumerated. Altogether, this review aims at gathering together the novel nanosystems for anti-infectious therapy, underlining the potential of DDSs to improve and optimize currently available antibiotic therapies in the context of lung infections.

1 February 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MMMaría Moreno-Sastre
María Moreno-Sastre
MPMarta Pastor
Marta Pastor
AEAmaia Esquisabel
Amaia Esquisabel
ESEulàlia Sans
Eulàlia Sans
MVMiguel Viñas
Miguel Viñas
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz

1 December 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MPMarta Pastor
Marta Pastor
MMMaría Moreno-Sastre
María Moreno-Sastre
AEAmaia Esquisabel
Amaia Esquisabel
ESEulàlia Sans
Eulàlia Sans
MVMiguel Viñas
Miguel Viñas
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz

2 October 2016 in Journal of Microencapsulation
Verified
Journal Article
Closed access
MMM. Moreno-Sastre
M. Moreno-Sastre
MPM. Pastor
M. Pastor
AEA. Esquisabel
A. Esquisabel
ESEulalia Sans
Eulalia Sans
MVM. Viñas
M. Viñas
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz
In the last decades, the encapsulation of antibiotics into nanoparticulate carriers has gained increasing attention for the treatment of infectious diseases. Sodium colistimethate-loaded solid lipid nanoparticles (Colist-SLNs) and nanostructured lipid carriers (Colist-NLCs) were designed aiming to treat the pulmonary infection associated to cystic fibrosis patients. The nanoparticles were freeze-dried using trehalose as cryoprotectant. The stability of both nanoparticles was analysed over one year according to the International Conference of Harmonisation (ICH) guidelines by determining the minimum inhibitory concentration (MIC) against clinically isolated Pseudomonas aeruginosa strains and by studying their physico-chemical characteristics. The results showed that Colist-SLNs lost their antimicrobial activity at the third month; on the contrary, the antibacterial activity of Colist-NLCs was maintained throughout the study within an adequate range (MIC ≤16 μg/mL). In addition, Colist-NLCs exhibited suitable physico-chemical properties at 5 °C and 25 °C/60% relative humidity over one year. Altogether, Colist-NLCs proved to have better stability than Colist-SLNs.